P2RY2 (Purinergic Receptor P2Y2)

📖 Wiki Page

gene2602 wordssynced 2026-04-02

P2RY2 (Purinergic Receptor P2Y2)

...

P2RY2 (Purinergic Receptor P2Y2)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">p2ry2</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>P2RY2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Purinergic Receptor P2Y2</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>11</td>
</tr>
<tr>
<td class="label">Genomic Location</td>
<td>11q13.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>5029</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>173415</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000165326</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9ULL8</td>
</tr>
<tr>
<td class="label">Gene Family</td>
<td>P2Y receptor family (GPCR)</td>
</tr>
<tr>
<td class="label">Protein Product</td>
<td>P2Y2 receptor, 43 kDa</td>
</tr>
<tr>
<td class="label">Agonist</td>
<td>EC50</td>
</tr>
<tr>
<td class="label">ATP</td>
<td>~1 μM</td>
</tr>
<tr>
<td class="label">UTP</td>
<td>~1 μM</td>
</tr>
<tr>
<td class="label">2-MeSATP</td>
<td>~0.1 μM</td>
</tr>
<tr>
<td class="label">Ap4A</td>
<td>~1 μM</td>
</tr>
<tr>
<td class="label">Antagonist</td>
<td>IC50</td>
</tr>
<tr>
<td class="label">Suramin</td>
<td>~100 μM</td>
</tr>
<tr>
<td class="label">PPADS</td>
<td>~50 μM</td>
</tr>
<tr>
<td class="label">Diquafosol</td>
<td>~10 μM</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Diquafosol</td>
<td>Agonist</td>
</tr>
<tr>
<td class="label">INS37217</td>
<td>Agonist</td>
</tr>
<tr>
<td class="label">Suramin</td>
<td>Antagonist</td>
</tr>
<tr>
<td class="label">AR-C118925</td>
<td>Antagonist</td>
</tr>
<tr>
<td class="label">Year</td>
<td>Milestone</td>
</tr>
<tr>
<td class="label">1995</td>
<td>P2Y2 cloning</td>
</tr>
<tr>
<td class="label">2000</td>
<td>Dual ATP/UTP recognition</td>
</tr>
<tr>
<td class="label">2006</td>
<td>CNS expression characterized</td>
</tr>
<tr>
<td class="label">2013</td>
<td>Neuroinflammation link</td>
</tr>
<tr>
<td class="label">2017</td>
<td>AD research</td>
</tr>
<tr>
<td class="label">2019</td>
<td>Therapeutic targeting</td>
</tr>
<tr>
<td class="label">2021</td>
<td>PD models</td>
</tr>
<tr>
<td class="label">2023</td>
<td>Novel therapeutics</td>
</tr>
<tr>
<td class="label">Species</td>
<td>ATP Sensitivity</td>
</tr>
<tr>
<td class="label">Human</td>
<td>High</td>
</tr>
<tr>
<td class="label">Mouse</td>
<td>Similar</td>
</tr>
<tr>
<td class="label">Rat</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Non-human primate</td>
<td>Similar to human</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">31 edges</a></td>
</tr>
</table>

Introduction

The P2RY2 gene encodes the P2Y2 receptor, a G protein-coupled receptor (GPCR) that responds to both adenine and uridine nucleotides, particularly ATP and UTP. P2Y2 is a unique member of the P2Y receptor family because it is activated by both ATP and UTP with similar potency, making it a central sensor of cellular stress and tissue damage. Beyond its well-characterized roles in airway and mucosal immunity, P2Y2 is increasingly recognized as an important mediator of neuroinflammation and neurodegenerative disease pathogenesis in Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders. [@burnstock1999]

P2Y2 is widely expressed throughout the central nervous system (CNS), with high levels in microglia, astrocytes, and neurons. The receptor signals through Gq proteins, activating phospholipase C (PLC) and leading to intracellular calcium mobilization, similar to P2Y1. However, P2Y2 also couples to Gi proteins in certain cell types, providing additional signaling complexity. The dual nucleotide specificity of P2Y2 makes it a critical sensor of cellular damage, as both ATP and UTP are released from damaged or stressed cells. [@chen2006]

Gene Overview

Gene Structure and Regulation

Genomic Architecture

The P2RY2 gene is located on chromosome 11q13.2 and consists of 2 exons spanning approximately 3.2 kilobases. The gene structure is conserved across mammals, though alternative splicing generates multiple transcript variants in some species.

Transcriptional Regulation

P2RY2 expression is dynamically regulated:

Inflammatory stimuli: TNF-α, IL-1β, and IFN-γ upregulate P2RY2 expression

Mechanical stress: Shear stress and stretch increase expression

Hypoxia: Hypoxic conditions induce P2RY2

Cellular damage: Injury and stress signals promote expression

Circadian regulation: Some diurnal variation in expression

Protein Structure and Function

Structural Features

The P2Y2 receptor is a typical class A GPCR with seven transmembrane domains:

N-terminal extracellular domain: Contains ligand-binding site

Transmembrane domains (TM1-TM7): Form the receptor core

Extracellular loops: Influence nucleotide specificity

Intracellular loops: Couple to G proteins

C-terminal tail: Contains regulatory sequences

Unique Ligand Specificity

P2Y2 is unique among P2Y receptors in responding to both purine and pyrimidine nucleotides:

Signaling Pathways

P2Y2 couples to multiple G proteins:

Gq/11: Primary coupling → PLCβ → IP3/DAG → Ca2+ release

Gi/o: Secondary coupling → inhibition of adenylate cyclase

G12/13: Cytoskeletal regulation through Rho GTPases

Normal Function in the Brain

Cellular Expression

P2Y2 receptors are expressed in multiple CNS cell types:

Microglia: High expression, particularly in activated states

Astrocytes: Moderate to high expression

Neurons: Lower expression, varies by region

Oligodendrocytes: Present, role in myelination

Endothelial cells: Contributes to vascular function

Physiological Roles

Damage sensing: ATP and UTP as danger signals

Immune surveillance: Microglial activation modulation

Calcium homeostasis: Regulates intracellular calcium

Membrane repair: Facilitates wound healing responses

Proliferation: Affects glial cell proliferation

Cytokine production: Modulates inflammatory responses

ATP and UTP Release

Understanding nucleotide release is key to P2Y2 function:

Cell damage: Massive ATP/UTP release from necrotic cells

Shear stress: Mechanical stimuli trigger release

Hypoxia: Ischemic conditions promote release

Exocytosis: Vesicular release in some cell types

Connexin/pannexin channels: Controlled release pathways

Role in Alzheimer's Disease

Evidence for P2Y2 Involvement

P2Y2 receptors are implicated in AD pathogenesis through multiple mechanisms:

Amyloid-beta interaction: Aβ can modulate P2Y2 expression and signaling

Neuroinflammation: P2Y2 contributes to chronic microglial activation

Calcium dysregulation: Altered P2Y2 signaling affects neuronal calcium homeostasis

Synaptic dysfunction: May contribute to synaptic loss

Mechanisms of Contribution

Pro-inflammatory signaling: P2Y2 activation leads to:

Cytokine and chemokine production
Microglial activation and morphologic changes
Oxidative stress generation

Calcium dysregulation: Contributes to:

Excitotoxicity
Mitochondrial dysfunction
Apoptotic pathways

Blood-brain barrier: P2Y2 may affect BBB integrity

Therapeutic Implications

P2Y2 targeting in AD:

Antagonists: May reduce neuroinflammation
Agonists: May promote neuroprotection through different mechanisms
Dual considerations: Cell-type specific effects matter
Challenges: Understanding timing and context

Role in Parkinson's Disease

Evidence for P2Y2 Involvement

P2Y2 contributes to PD through:

Dopaminergic neuron vulnerability: P2Y2-mediated inflammation affects survival

Microglial activation: Chronic activation in substantia nigra

α-Synuclein pathology: Interactions with protein aggregation

Mitochondrial dysfunction: Links to energy metabolism

Mechanisms

Neuroinflammation: P2Y2 promotes:

Pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6)
Oxidative stress through NADPH oxidase activation
Nitric oxide production

Neuronal dysfunction: Contributes to:

Calcium dysregulation
Energy failure
Apoptosis

Experimental Models

MPTP model: P2Y2 modulates dopaminergic neuron loss
α-Synuclein models: P2Y2 affects pathology progression
In vitro: P2Y2 activation promotes neurotoxicity

Role in Neuroinflammation

Microglial Activation

P2Y2 is a key regulator of microglial responses:

Chemotaxis: Guides migration to damaged areas

Activation: Promotes pro-inflammatory phenotype

Phagocytosis: Modulates debris clearance

Cytokine production: Regulates inflammatory mediator release

Signaling Pathways

Mermaid diagram (expand to render)

Cross-talk

P2Y2 interacts with multiple signaling pathways:

TLRs: Synergistic inflammatory activation

P2X7: Cooperates in inflammasome activation

NLRP3: Potentiates inflammasome responses

Growth factor receptors: Transactivation

Role in Neurovascular Function

Blood-Brain Barrier

P2Y2 influences BBB function:

Endothelial function: Regulates tight junction proteins

Permeability: Modulates BBB integrity

Leukocyte trafficking: Affects immune cell entry

Angiogenesis: Influences blood vessel formation

Stroke and Ischemia

P2Y2 in cerebral ischemia:

Early injury: Mediates excitotoxic damage

Inflammation: Contributes to post-ischemic inflammation

Recovery: May affect repair mechanisms

Therapeutic window: Timing of intervention critical

Therapeutic Targeting

Drug Development

Challenges

BBB penetration: Most compounds don't cross

Species differences: Pharmacology varies

Cell-type effects: Agonists vs. antagonists

Timing: Critical intervention window

Novel Approaches

Brain-penetrant compounds: New chemical entities

Allosteric modulators: Improved selectivity

Gene therapy: CNS-targeted delivery

Combination therapy: Multi-target approaches

Molecular Interactions

Protein Interactions

G proteins: Gq/11 primary, Gi/o secondary

β-arrestin: Receptor desensitization

GRKs: Phosphorylation regulation

Integrins: Functional cross-talk

Signaling Network

Mermaid diagram (expand to render)

Genetic Associations

P2RY2 Polymorphisms

rs2854237: Associated with inflammatory disease
rs1714719: Modified asthma risk
rs4385544: Potential disease associations
Population-specific variants may influence susceptibility

Research Timeline

Key Publications

[Burnstock G. Purinergic signaling: an expanding concept. Prog Brain Res. 1999](https://pubmed.ncbi.nlm.nih.gov/10625241/)

[Chen Y, et al. P2Y2 receptors in the central nervous system. J Neurosci Res. 2006](https://pubmed.ncbi.nlm.nih.gov/16511850/)

[Fischer D, et al. P2Y2 receptor in neurodegeneration. Neuropharmacology. 2013](https://pubmed.ncbi.nlm.nih.gov/23079211/)

[Schneider M, et al. P2Y2 in neuroinflammation and Alzheimer's disease. J Neuroinflammation. 2017](https://pubmed.ncbi.nlm.nih.gov/28173852/)

[Yang Y, et al. P2Y2 in microglial activation and neuroinflammation. Glia. 2018](https://pubmed.ncbi.nlm.nih.gov/29135145/)

[Lee DH, et al. P2Y2 receptors as therapeutic target in AD. Pharmacol Res. 2019](https://pubmed.ncbi.nlm.nih.gov/31150635/)

[Petersen C, et al. Nucleotide signaling in Parkinson's disease. Front Cell Neurosci. 2020](https://pubmed.ncbi.nlm.nih.gov/32153384/)

[Choi JH, et al. P2Y2 in alpha-synuclein pathology. Neurobiol Dis. 2021](https://pubmed.ncbi.nlm.nih.gov/33823356/)

[Hernandez MG, et al. Targeting P2Y2 for neurodegenerative disease therapy. Expert Opin Ther Targets. 2023](https://pubmed.ncbi.nlm.nih.gov/36626188/)

[Kim H, et al. P2Y2 in neurovascular unit dysfunction. Stroke. 2024](https://pubmed.ncbi.nlm.nih.gov/37856789/)

Animal Models

Genetic Models

P2Y2 knockout mice: Viable with mucosal and immune phenotypes
Conditional knockout: Tissue-specific deletion
Humanized models: Improved translation

Disease Models

APP/PS1 mice: P2Y2 modulates pathology
MPTP model: P2Y2 affects dopaminergic neuron loss
Ischemia model: P2Y2 blockade provides neuroprotection

Conclusions

The P2RY2 gene encodes a unique purinergic receptor that responds to both ATP and UTP, making it a central sensor of cellular stress and tissue damage in the CNS. P2Y2 plays complex roles in neuroinflammation and neurodegenerative disease, with contributions to microglial activation, cytokine production, and neuronal dysfunction in AD and PD. Therapeutic targeting of P2Y2 faces challenges related to BBB penetration and the dual nature of receptor signaling (pro-inflammatory vs. protective). Understanding the cell-type-specific and context-dependent functions of P2Y2 will be critical for developing effective neuroprotective strategies. The development of brain-penetrant selective agonists and antagonists, along with biomarker-driven patient selection, represents a promising avenue for translating P2Y2 research into disease-modifying therapies for neurodegenerative conditions.

Brain Region Expression

Hippocampus

The hippocampus shows dynamic P2Y2 expression:

CA1 pyramidal neurons: Respond to ATP/UTP release

CA3 region: Involved in pattern separation

Dentate gyrus: Neural stem cell regulation

Entorhinal cortex input: Synaptic plasticity modulation

Functions:

Memory formation and consolidation
Spatial navigation
Injury response mechanisms
Seizure modulation

Cortex

Cortical P2Y2 distribution:

Layer 2/3: Upper cortical layers with high expression

Layer 4: Thalamic input processing

Layer 5: Cortical output neurons

Layer 6: Subcortical projections

Roles:

Sensory integration
Motor coordination
Cognitive processing
Corticothalamic feedback

Substantia Nigra

P2Y2 in basal ganglia:

Pars compacta: Dopaminergic neuron region

Pars reticulata: Output structure

Ventral tegmental area: Reward pathway

Striatal connections: Motor control

Clinical significance:

Parkinson's disease vulnerability
Dopaminergic neuron survival
Movement control
Therapeutic targeting

White Matter

P2Y2 in white matter tracts:

Corpus callosum: Interhemispheric communication

Internal capsule: Motor pathways

Cerebellar peduncles: Cerebellar connections

Spinal cord tracts: Descending pathways

Functions:

Oligodendrocyte function
Myelin maintenance
Axonal health
Injury responses

Cell Type-Specific Functions

Microglial P2Y2

Microglia show highest P2Y2 expression:

Activation states:

Resting/surveiling microglia
Primed microglia
Activated/reactive microglia
Dystrophic/age-associated microglia

Functional outputs:

Cytokine production (IL-1β, TNF-α, IL-6)
Chemokine release
Phagocytosis modulation
ROS/RNS generation
Neurotoxicity vs. neuroprotection

Neuronal P2Y2

Neuronal P2Y2 functions:

Synaptic activity:

Presynaptic neurotransmitter release
Postsynaptic response modulation
Activity-dependent plasticity

Neuronal health:

Metabolic regulation
Calcium homeostasis
Survival signaling
Axonal protection

Astrocytic P2Y2

Astrocyte P2Y2 roles:

Homeostatic functions:

Potassium buffering
Water balance
Metabolic support
Ion homeostasis

Reactive responses:

Glial scar formation
Injury containment
Inflammation modulation
Tissue repair

Disease Mechanisms in AD

Amyloid Cascade Interaction

P2Y2 intersects with Aβ pathology:

Aβ-induced P2Y2 expression: Aβ oligomers upregulate P2Y2

P2Y2-mediated inflammation: Drives chronic neuroinflammation

Synaptic dysfunction: Contributes to memory impairment

Neuronal death: Exacerbates degeneration

Tau Pathology Connection

P2Y2 and tau:

Hyperphosphorylation: P2Y2 promotes tau kinases

Tau spread: Microglial P2Y2 affects propagation

NFT formation: Acceleration of aggregation

Neuronal vulnerability: Synergistic toxicity

Therapeutic Targeting in AD

Current approaches:

Antagonists: Reduce neuroinflammation
Agonists: May promote neuroprotection
Gene therapy: Modulate expression
Combination: Multi-target strategies

Disease Mechanisms in PD

Dopaminergic Vulnerability

P2Y2 in substantia nigra:

ATP release: Damage signals trigger release

UTP signaling: Additional activation

Microglial activation: Chronic inflammation

Neuron loss: Progressive degeneration

α-Synuclein Interactions

P2Y2 and α-Syn:

Aggregation: P2Y2 may influence nucleation

Spread: Propagation mechanisms

Toxicity: Synergistic cell death

Clearance: Autophagy modulation

Therapeutic Strategies

Targeting P2Y2 in PD:

Neuroprotection: Preventing neuron loss
Anti-inflammatory: Reducing microglial activation
Disease modification: Slowing progression
Biomarker development: Patient selection

Aging and Neurodegeneration

Age-Related Expression Changes

Aging affects P2Y2:

Upregulation: Increased expression with age

Signaling alterations: Dysregulated responses

Functional consequences: Impaired resolution

Cumulative effects: Contributing to disease

Intervention Strategies

Modulating aging effects:

Lifestyle: Exercise, diet impacts

Pharmacological: Targeted interventions

Preventive: Early intervention

Regenerative: Promoting repair

Comparative Pharmacology

Species Differences

P2Y2 pharmacology shows species variation:

Translation Implications

Species differences affect:

Preclinical to clinical translation
Dose selection
Efficacy predictions
Safety assessments

Drug Development Pipeline

Clinical Candidates

Current development status:

Phase I: First-in-human studies beginning
Preclinical: Multiple compounds in development
Research: Novel chemical entities
Repurposing: Existing drugs with new indications

Novel Delivery Methods

Emerging approaches:

Nanoparticle delivery: Targeted brain delivery

Pro-drug strategies: Improved BBB penetration

Intranasal delivery: Direct nose-to-brain

Focused ultrasound: Temporary BBB opening

Exosome loading: Cell-derived vesicles

Regulatory Status

Current Approvals

P2Y2-related drugs:

Diquafosol: Approved for dry eye (topical)
Other agonists: Research stage
Antagonists: Preclinical/clinical

Development Challenges

BBB penetration: Primary obstacle
Safety profile: Chronic dosing concerns
Efficacy: Demonstrating disease modification
Biomarkers: Patient selection needs

Research Gaps

Unmet Needs

Selective compounds: Brain-penetrant and selective

Understanding dual signaling: Agonist vs. antagonist

Cell-type targeting: Selective modulation

Biomarker development: Patient stratification

Combination approaches: Multi-target strategies

Future Directions

Structural studies: Guide drug design
Cell-type specific functions: Targeted approaches
Biomarker qualification: Precision medicine
Gene therapy: Novel modalities

Additional Clinical Considerations

Patient Stratification

Genetic markers: P2RY2 polymorphisms affecting drug response

Expression levels: Tissue P2Y2 as predictive biomarker

Disease stage: Early vs. late intervention

Comorbidities: Cardiovascular, metabolic conditions

Medication history: Prior NSAID use, antiplatelet therapy

Safety Monitoring

Cardiovascular: Blood pressure, heart rate monitoring

Neurological: Cognitive function assessments

Inflammatory markers: Cytokine levels, ESR/CRP

Imaging: MRI for disease progression

Functional measures: Clinical rating scales

Clinical Trial Design

Study populations: Defining inclusion/exclusion criteria

Endpoints: Primary and secondary outcomes

Duration: Long-term follow-up requirements

Statistical considerations: Power analysis, sample size

Regulatory pathways: Fast track, breakthrough therapy designations

Pathway Diagram

The following diagram shows the key molecular relationships involving P2RY2 (Purinergic Receptor P2Y2) discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →